AG Insurance-Soudal's Urska Zigart suffered a fractured jaw after a high-speed crash at the final kilometre of stage two in Locarno during the Tour de Suisse Femmes. The Slovenian rider, 29, lost control over a speedbump, skidded meters before stopping. Her team confirmed hospital transport, with medical staff diagnosing the jaw fracture but no other injuries. Zigart's partner, Tadej Pogacar—a four-time Tour de France winner—was nearby in the men’s race when she became motionless on the tarmac. Pogacar, leading the general classification, later spoke with her, indicating she was conscious. The accident raises questions about her recovery timeline and potential impact on her season. For now, AG Insurance-Soudal emphasizes prioritizing her health over race outcomes.

Zigart’s crash occurred in a critical moment of the race, highlighting the physical risks inherent in high-speed cycling. While Pogacar’s dominance in the men’s Tour de Suisse remains unchallenged, Zigart’s injury underscores the fragility of female riders in competitive stages. Her partnership with Pogacar adds emotional weight to the incident, as both represent Slovenia’s cycling prowess. The team’s focus on medical evaluation over immediate race feedback signals a measured approach to her treatment. Zigart’s ability to communicate post-accident suggests some resilience, but a fractured jaw typically requires weeks of recovery, potentially sidelining her for the remainder of the event.

The implications extend beyond Zigart’s individual campaign. If she cannot return to racing soon, it may affect AG Insurance-Soudal’s strategy for the Tour de Suisse Femmes. Meanwhile, Pogacar’s continued success in the men’s race reinforces his status as a titan of cycling. However, the incident serves as a stark reminder of the sport’s dangers, even for elite athletes. Zigart’s diagnosis contrasts with Pogacar’s unscathed performance, illustrating how similar risks can yield vastly different outcomes. As the race progresses, fans will watch for updates on her recovery while acknowledging the broader conversation about safety in professional cycling. The team’s silence on further details keeps the focus on medical progress rather than speculative timelines.